Rapport Therapeutics, Inc. (RAPP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Rapport Therapeutics reported revenue of $0. Net income was -$111.5M, or -$2.86 per diluted share. Operating activities generated -$87.5M of cash, leaving -$88.1M of free cash flow. At fiscal year end, Rapport Therapeutics held $512.4M in total assets against $27.8M in total liabilities, including $52.6M of cash and equivalents.
Open the full interactive Rapport Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Rapport Therapeutics Key Stats
| Share Price | $28.99 |
|---|---|
| Market Cap | $1.38B |
| 52-Week Range | $24.37 – $52.50 |
| Shares Outstanding | 47.5 million (basic, 2026 Q2) |
Rapport Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$83.1M | -$125.1M |
| Pre-Tax Income | -$78.3M | -$111.5M |
| Income Tax | $0 | $0 |
| Net Income | -$78.3M | -$111.5M |
| Diluted EPS | -$3.78 | -$2.86 |
Rapport Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $20.0M | $0 |
| Net Income | -$26.9M | -$33.8M | -$19.9M | -$56.6M |
| Diluted EPS | -$0.71 | -$0.87 | -$0.42 | -$1.19 |
Rapport Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $56.8M | $52.6M |
| Current Assets | $309.8M | $498.6M |
| Total Assets | $314.9M | $512.4M |
| Current Liabilities | $8.8M | $19.0M |
| Total Liabilities | $9.5M | $27.8M |
| Shareholders' Equity | $305.4M | $484.7M |
Rapport Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$64.8M | -$87.5M |
| Cash From Investing | -$170.1M | -$187.5M |
| Cash From Financing | $221.6M | $270.8M |
| Free Cash Flow | -$67.2M | -$88.1M |
Figures from Rapport Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Rapport Therapeutics financials page for every line item.
Rapport Therapeutics Company Profile
| Ticker | RAPP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0002012593 |
Frequently Asked Questions
What was Rapport Therapeutics' revenue in fiscal 2025?
Rapport Therapeutics (RAPP) reported revenue of $0 for fiscal 2025.
What was Rapport Therapeutics' net income in fiscal 2025?
Rapport Therapeutics reported net income of -$111.5M for fiscal 2025.
What was Rapport Therapeutics' earnings per share (EPS) in fiscal 2025?
Rapport Therapeutics' diluted EPS was -$2.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Rapport Therapeutics generate in fiscal 2025?
Rapport Therapeutics generated -$88.1M of free cash flow in fiscal 2025.
What was Rapport Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Rapport Therapeutics reported revenue of $0.
How many shares of Rapport Therapeutics are outstanding?
Rapport Therapeutics reported a weighted average of 47.5 million basic shares outstanding in 2026 Q2.
What is Rapport Therapeutics' market cap?
Based on its latest closing price, Rapport Therapeutics (RAPP) has a market capitalization of about $1.38B.
When does Rapport Therapeutics' fiscal year end?
Rapport Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Rapport Therapeutics headquartered?
Rapport Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.